Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Taylor Swift and Travis Kelce doing Coachella in style! They will be staying at a TOP luxury membersPremier League clubs vote unanimously for major new change to the offside ruleBlunders cost Crusaders dearly in loss to WaratahsMan United are 'playing like a small club', blasts Roy Keane after their 2Blunders cost Crusaders dearly in loss to WaratahsAtletico Madrid star reveals the footballers'Diego Simeone is involved in feisty touchline bustBlake Lively says she dreamed up husband Ryan Reynolds as she promotes their new animated film IFAnge Postecoglou admits he has not watched back Tottenham's humiliating 6BBC announce Tom Hiddleston is set to return to The Night Manager for two more series
2.2105s , 6574.53125 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Global Glossary news portal